Brief: Sanofi and IGM Biosciences to collaborate in the sphere of oncology, IGM to receive $150 million upfront payments

IGM Biosciences

29/03/2022 06:03

March 29 (Reuters) - Sanofi  SASY.PA :
    * PRESS RELEASE: SANOFI AND IGM BIOSCIENCES ANNOUNCE
COLLABORATION
AGREEMENT FOR ONCOLOGY, IMMUNOLOGY AND INFLAMMATION TARGETS
    * AND IGM BIOSCIENCES ANNOUNCE COLLABORATION AGREEMENT FOR
ONCOLOGY, IMMUNOLOGY AND INFLAMMATION TARGETS
    * IGM TO RECEIVE $150 MILLION UPFRONT PAYMENTS, POTENTIALLY
OVER
$6 BILLION IN AGGREGATE DEVELOPMENT, REGULATORY AND COMMERCIAL
MILESTONES
    * /IGM: COLLABORATION TO CREATE, DEVELOP, MANUFACTURE AND
COMMERCIALIZE NEW CLASS OF POTENTIAL THERAPEUTICS COMBINING
SUPERIOR FEATURES OF MULTI-VALENT IGM ANTIBODIES OVER
CONVENTIONAL IGG ANTIBODIES FOR STIMULATING CELL SURFACE
RECEPTORS
    * SANOFI HAS ALSO EXPRESSED AN INTEREST IN PURCHASING UP TO
$100M
OF IGM NON-VOTING COMMON STOCK IN A PUBLIC FINANCING.

Source text for Eikon:  ID:nGNE4QS0P6 
Further company coverage:  SASY.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))